Background: This study aimed to compare the therapeutic efficacy of transcatheter arterial chemoembolization (TACE) combined with either I seed implantation or I seed implantation and intra-tumor injection of cisplatin in treating hepatocellular carcinoma (HCC).
Methods: A total of 100 patients with HCC were analyzed. The control group (n = 50) received TACE combined with I seed implantation therapy. The therapy group (n = 50) was treated with an intra-tumor injection of cisplatin along with TACE and I seed implantation therapy. After treatment, routine blood, liver and kidney function, tumor volume, T lymphocyte subset count (CD3, CD4, and CD8), implanted metastases, and survival were studied.
Results: The tumor volume decreased by 27.4% on average in the control group, and by 38.6% in the therapy group. Alpha fetoprotein (AFP) level decreased in all cases, and it was significantly lower in the therapy group than in the control group. Remote metastasis was observed in both groups (7 in the control group and 3 in the therapy group). No significant difference in routine blood, liver and kidney function, and T-lymphocyte subset counts were found between the two groups. Eight patients died of metastases in the control group and 2 in the therapy group at 1-year follow-up (P < 0.05).
Conclusion: TACE combined with either I seed implantation or I seed implantation and intra-tumor injection of cisplatin was effective for the treatment of HCC. Of the 2 combination therapies, TACE combined with I seed implantation and intra-tumor injection of cisplatin was more effective for the treatment of HCC.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.4103/ijc.IJC_635_18 | DOI Listing |
Phys Med Biol
January 2025
Department of Medical Physics, Jeroen Bosch Ziekenhuis, Henri Dunantstraat 1, 's-Hertogenbosch, 5223GZ, NETHERLANDS.
The treatment of breast cancer during pregnancy requires careful consideration of consequences for both maternal and fetal health. In non-pregnant patients, the use of radioactive iodine-125 (125I)-seeds is standard practice for localising non-palpable breast tumors before breast-conserving surgery. However, the use of 125I-seeds in pregnant patients has been avoided due to concerns about fetal radiation exposure.
View Article and Find Full Text PDFJ Hepatocell Carcinoma
January 2025
Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, People's Republic of China.
Background & Aims: The effect of transarterial chemoembolization (TACE) plus radiofrequency ablation (RFA) (TACE-RFA) for hepatocellular carcinoma (HCC) in high-risk locations is not satisfactory. The aim of this study was to compare the clinical outcomes of TACE-RFA plus iodine-125 (I) seed implantation (TACE-RFA-I) therapy with those of TACE-RFA for unresectable HCC (≤5 cm) in high-risk locations.
Methods: From January 2010 to June 2023, the clinical data of 126 patients with unresectable HCC (≤5 cm) in high-risk locations who received TACE-RFA-I or TACE-RFA treatment were retrospectively analyzed.
Proc Natl Acad Sci U S A
January 2025
Center for Brain Circuit Therapeutics, Department of Neurology, Brigham & Women's Hospital, Harvard Medical School, Boston, MA 02115.
Deep brain stimulation is an efficacious treatment for dystonia. While the internal pallidum serves as the primary target, recently, stimulation of the subthalamic nucleus (STN) has been investigated. However, optimal targeting within this structure and its surroundings have not been studied in depth.
View Article and Find Full Text PDFRep Pract Oncol Radiother
December 2024
Department of Biomedical Physics, Faculty of Physics, Adam Mickiewicz University, Poznań, Poland.
Background: The purpose of this study is to determine the effect of the type of I-125 radioactive source on dose distribution in the planning process of ultra-low dose rate (uLDR) prostate brachytherapy.
Material And Methods: 7 patients who had undergone brachytherapy in our center were included in the study. Dose in five geometrical points were analyzed for 12 types of implants that are available on the market.
World J Stem Cells
December 2024
Department of Orthopedics, Children's Hospital of Fudan University & National Children's Medical Center, Shanghai 201102, China.
Background: The gold standard of care for patients with severe peripheral nerve injury is autologous nerve grafting; however, autologous nerve grafts are usually limited for patients because of the limited number of autologous nerve sources and the loss of neurosensory sensation in the donor area, whereas allogeneic or xenografts are even more limited by immune rejection. Tissue-engineered peripheral nerve scaffolds, with the morphology and structure of natural nerves and complex biological signals, hold the most promise as ideal peripheral nerve "replacements".
Aim: To prepare allogenic peripheral nerve scaffolds using a low-toxicity decellularization method, and use human umbilical cord mesenchymal stem cells (hUC-MSCs) as seed cells to cultivate scaffold-cell complexes for the repair of injured peripheral nerves.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!